touchCONGRESS Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022?

In this interview Professor Saglio answers the following questions:

• When considering the new 96-week data for asciminib from the ASCEMBL trial, how do you think these results will impact clinical practice?
• In patients with absence of an optimal response on therapy, what can we learn from new data on switching TKIs?
• What have we learnt about the clinical considerations for TKI discontinuation?
• Extended use of TKIs is now commonplace; what safety aspects have we seen from long-term follow-up studies?
• How should dose modifications be used for TKIs in clinical practice?

Giuseppe Saglio is emeritus professor of haematology and internal medicine at the University of Turin, Italy. Prof. Saglio has been coordinator of the PhD programme in medicine and experimental therapy at the University of Turin and director of the Department of Clinical and Biological Sciences at the same university. He has published more than 600 peer-reviewed articles in the fields of molecular pathogenesis of haematological diseases, molecularly targeted therapy and molecular characterization of haematological malignancies. In 2017, Prof. Saglio was nominated Knight of the Italian Republic for scientific merits and for his long service to the Italian University.

Professor Giuseppe Saglio discloses: Speaker’s bureau and scientific advisory board fees from BMS, Incyte, Novartis and Pfizer.

In this interview Professor Mahon answers the following questions:

• When considering the new 96-week data for asciminib from the ASCEMBL trial, how do you think these results will impact clinical practice?
• In patients with absence of an optimal response on therapy, what can we learn from new data on switching TKIs?
• What have we learnt about the clinical considerations for TKI discontinuation?
• Extended use of TKIs is now commonplace; what safety aspects have we seen from long-term follow-up studies?
• How should dose modifications be used for TKIs in clinical practice?

François-Xavier Mahon is professor and senior house physician at the University of Bordeaux, France. He graduated in clinical haematology from the Faculty of Medicine, University of Bordeaux and received his PhD for his work on the topic ‘Selection of normal cells in chronic myeloid leukaemia (CML)’. Prof. Mahon completed a research fellowship at Imperial College London, UK. He is a member of the American Society of Hematology (ASH), European Haematology Association (EHA), French Society of Haematology, European Investigation of Chronic Myeloid Leukemia (EICML), European School of Haematology (ESH), European LeukemiaNet (ELN), International CML Foundation (iCMLf), Society of Hematology and Oncology (SOHO).

He is the former president of the French Group of CML (FI-LMC) and currently the vice president and secretary of Unicancer-France. He is general director of the Institut Bergonié (Comprehensive Cancer Centre of Bordeaux and South West of France) and director of the Mammary and Leukemic Oncogenesis Group, University of Bordeaux, INSERM Research (Unit U1218). He was awarded the John Goldman prize from the International Chronic Myeloid Leukemia Foundation (iCMLf) in 2019.

Prof. Mahon has authored or co-authored more than 250 articles in peer reviewed journals.

Professor François-Xavier Mahon has no interests/relationships or affiliations to disclose in relation to this activity.

In this interview Professor Niederwieser answers the following questions:

• When considering the new 96-week data for asciminib from the ASCEMBL trial, how do you think these results will impact clinical practice?
• In patients with absence of an optimal response on therapy, what can we learn from new data on switching TKIs?
• What have we learnt about the clinical considerations for TKI discontinuation?
• Extended use of TKIs is now commonplace; what safety aspects have we seen from long-term follow-up studies?
• How should dose modifications be used for TKIs in clinical practice?

Dietger Niederwieser is professor of medicine and the head of the Division of Haematology, Oncology and Haemostasis/Thrombosis at the University Hospital Leipzig, Germany. Prof. Niederwieser has authored over 400 publications in peer-reviewed journals and has held a number of society memberships, including board member of the Austrian Society of Haematology and Oncology and member of the European Haematology Association. Prof. Niederwieser was the secretary of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) between 1991 and 2000, and the Chairman of the Chronic Leukaemia Working Party of the EBMT between 2000 and 2006. He was appointed president of the EBMT in 2006 and of the Worldwide Network for Blood and Marrow Transplantation. He received the title of Dr honoris causa from the University of Thessaloniki, Greece in 2017.

Professor Dietger Niederwieser discloses: Advisory board fees from Cellectis. Speaker’s bureau fees from Daiichi and Novartis.